StockWatch
·
INSECTICIDES (INDIA) LTD. · QQ2 FY-2027 · THE CALL

Strong pipeline, soft quarter; margin compression raises near-term questions

The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.

Q2 FY27 resultsINSECTICIDINSECTICIDES (INDIA) LTD.12 Nov 2026 · 6 min read
Verdict

Hold

confidence 6/10

Credibility

Grade B

Guided 50–60% Kaeros CAGR; now raising to 50%+ with ₹200 Cr target. New intl guidance (₹500 Cr, 5Y) adds specificity. But Q2 missed on margin expansion and volume stabilization expectations.

Short-term outlook

Cautiously Optimistic

next 1–2 quarters

Long-term outlook

Optimistic

multi-year

Management is executing a credible long-term transformation—Kaeros 50%+ CAGR, international CDMO expansion, 30+ molecule pipeline—but Q2 delivery is soft and near-term catalysts delayed. Revenue growth is 7.6%, PAT down 5%, gross margins compressing 80 bps YoY, and working capital has deteriorated ₹34 Cr. Execution risk on capex (Dahej, Sotanala) and margin pressure from weather/commodity volatility remain near-term headwinds.

₹686.3 Cr

Revenue · +7.6% YoY

₹56.2 Cr

Reported PAT · −5% YoY

Compressing

Margins · vs guidance: Mixed

Did the claims hold up?

Management's claims vs. the numbers

8% revenue growth in Q2

MET

7.6% YoY growth; ₹686.3 Cr vs ₹637 Cr prior year

Gross margin 33.7% in Q2

MET

33.7% reported; compressing from 34.5% prior year

EBITDA 13.5%, PAT ₹56 Cr in Q2

MET

OPM 13.5%, PAT ₹56.2 Cr match exactly

Volume growth negative, value growth driving performance

MET

Admitted 6–7% volume decline; revenue +7.6% means value/mix raised by ~14–15%

Working capital improving via operational focus

MISS

WC days 158 (H1 FY27) vs 151 (H1 FY26); inventory ₹814 Cr vs ₹744 Cr; net WC ₹1,000 Cr vs ₹966 Cr — deteriorating

PAT margins on track, profitability intact

OVERSTATED

PAT ₹56.2 Cr vs ₹59.2 Cr prior year = -5% YoY; NPM 8.2% is stable but absolute PAT down

Earnings quality

What changed since the last call

Deltas vs. the prior call

Kaeros guidance firmed

Upgrade

Prior: '50–60% CAGR.' Now: ₹125 Cr brand target, ₹200 Cr gross FY27/28, 50%+ CAGR. Standalone Kaeros could reach ₹200 Cr by year-end, then double.

International business newly quantified

New

First explicit targets: 40–50% CAGR, ₹500 Cr total over 5 years from intl markets. Prior call had no international revenue guidance.

Premium product mix target raised

Upgrade

New: 70% premium product mix target. Prior call silent on this specific ratio.

Volume trend remains negative

Downgrade

Management admitted 6–7% volume decline in Q2 and expectations for flat/slightly negative FY27 volume. Prior call hinted at stabilization.

Capex timeline slipped slightly

Downgrade

Dahej was 'first half of year'; now Q3. Sotanala was 'next fiscal'; now Q4 formulation launch implied. Minor slip but shows execution pressure.

The Q&A

Analysts pressed hard on volume, international progress, capex delays, margin outlook. Rajesh held firm, providing detail (15+ AIs filed, 28 molecules in domestic portfolio, 800k+ Kaeros distributors appointed). No evidence of evasion, but acknowledged headwinds without conceding near-term margin recovery.

The exchanges that mattered

Volume and segment growth — Bharat Gupta, Fair Value Capital

Answered

Negative volume in quarter (6–7% drop). Value growth 4–5% from premium mix. Maharatna seen improvement; focus on premium products, not volume chase.

Kaeros scaling — Bharat Gupta, Fair Value Capital

Answered

Kaeros doing very well, ₹75 Cr brand in FY26, ₹114 Cr H1 FY27 sales. Target ₹125–200 Cr gross by year-end; can double next year. 50%+ CAGR trajectory.

Product pipeline and 9(3) launches — Bharat Gupta, Fair Value Capital

Partial

30 molecules in development; 12 already filed. Nissan new product first, then 9(3) mixtures. Oil product delayed pending CIB clearance; timing uncertain but expected next season.

Dahej and Sotanala capex status — Praneeth, SJ Investments

Answered

Dahej now expected Q3 completion (was H1). Plant partially in production; full swing after December restart. Sotanala formulation target April; technical manufacturing next fiscal.

Volume outlook for full year — Praneeth, SJ Investments

Answered

Not a growth year for volume; ending roughly flat. Very confident value growth will offset; H2 improvements expected.

Margin trajectory and premiumization — Praneeth, SJ Investments

Partial

Already at 33–34% level. Target to match industry best step-by-step. ~1% growth possible on average; some years may jump 2–3%.

Team expansion and cost inflation — Praneeth, SJ Investments

Answered

Current on-roll team ~750 (parity with best in industry). H2 additions limited to third-party roles. No major headcount plans this fiscal.

Distributor and retailer tracking systems — Praneeth, SJ Investments

Answered

Have DMS but informal tracking too (QR system, Beetroot platform in Kaeros). Market visibility ~15–20% currently; aiming 60–70% with scheme rollouts and enhanced participation.

International and CDMO strategy — Yash, Grit Securities

Answered

Started with brand/white label; now pivoting to technicals. Registrations in Americas, Europe, ASEAN. 15 AIs filed; targeting traction in technicals market. CDMO model emerging with partners (Japanese JVs, developing relationships).

CDMO business model clarity — Yash, Grit Securities

Partial

CDMO = contracted business where company manufactures molecule exclusively/semi-exclusively for partner (vs. China models). Developing parallel supplier relationships. Sotanala and Dahej plants positioned to qualify for CDMO contracts.

OAT Agrio product development — Santosh Shetty, DD Capital

Partial

Target 2027 launch; application filed, Schedule inclusion pending. If approved, launch possible within ~1 year. Once first product launches, start second; strong pipeline of 3–5 launches expected. Spinoace/Granuvia new technologies with lukewarm market response; recovery expected in H2 rabi crop.

R&D investment and molecule portfolio — Santosh Shetty, DD Capital

Answered

Innovation/R&D focused. 4 R&D centers across India; spend ~₹12–20 Cr booked as marketing (not classified as R&D for tax purposes). 35 molecules registered (formulations + technicals); 12+ filed; expect 30+ total in next 2–3 years. R&D = performance, not show.

Kaeros 200 Cr potential and standalone runway — Rajiv Jain, Arcane Investments

Answered

Kaeros ~₹75 Cr gross in FY26; ₹100+ Cr sales in H1 FY27. Target ₹125 Cr brand in FY27, ₹200 Cr gross by fiscal-end or next year. Kaeros stand-alone could touch ₹200 Cr, then double. 50%+ CAGR expected.

Premium product mix and margin impact — Rajiv Jain, Arcane Investments

Answered

Premium products currently ~60%+ of mix. Target 70% over 2–3 years. Strategy formed years ago when premium contributed 50%. Growth coming from Kaeros, Maharatna volumes. No sales push needed; farmer demand strong.

Returns and PAT loss provisions — Praneeth, SJ Investments

Partial

Q2 and H1 numbers shared; returns high in H1 but normal going forward. Q3 will be positive recovery; H2 should show improvement. Loss to PAT margin is ~crore level in Q2; H2 expected better, recovery visible.

Guidance

Forward guidance and management's confidence

Kaeros ₹200 Cr gross turnover by FY27/28

High

Currently ₹114 Cr H1; targeting ₹125–200 Cr by year-end or next fiscal. Standalone possible. 50%+ CAGR.

International ₹500 Cr target over 5 years, 40–50% CAGR

Medium

Currently ~5% of revenue; 15+ AIs in development; registrations in-progress. Long cycle time; execution risk high.

FY27 full-year volume flat, value growth positive

Medium

Q2 saw -6–7% volume decline; expecting stabilization in H2. Value mix shift to continue offsetting volume.

Gross margin improvement ~1–3% annually

Low

Currently 33.7% (Q2); down 80 bps YoY. Premiumization strategy in place, but near-term compression evident. Target to step-by-step improve toward industry best.

EBITDA margin 12–14% range

Medium

Q2 at 13.5%; H1 at 12.3%. Mix of Kaeros (high-margin nascent) and core (margin-compressed) businesses.

PAT margin stabilization post-Q2 weakness

Medium

H1 PAT ~₹100 Cr combined. Management notes 'recovery visible in H2' but cannot guarantee near-term margin expansion.

Dahej DCS plant full commission by Q3 FY27 (Dec 2026)

Medium

80% capitalized; expected ₹30–40 Cr total. Maintenance capex to normalize post-completion.

Sotanala formulation unit startup Q4; technical manufacturing next fiscal

Medium

Formulation April target (post-Diwali shutdown), technical manufacturing to start full next fiscal.

Risks the call surfaced

Ranked by how much they should concern a holder

Margin compression sustained

Medium

Gross margin down 80 bps YoY to 33.7%. Premiumization narrative not translating to expansion. If volume decline persists and mix shift slows, margin could compress further. Industry consolidation may pressure pricing.

Volume stabilization delayed

Medium

Q2 saw 6–7% volume decline. Management confident in value offset, but absolute volume headwind persists. If farmer sentiment remains weak or monsoon impact extends, stabilization could slip into FY28.

Working capital deterioration

Medium

WC days increased to 158 from 151. Inventory up ₹70 Cr (₹744→₹814 Cr), debtors up ₹76 Cr (₹643→₹719 Cr). Creditors up but not in line. If this trend continues, cash generation could be stressed, constraining capex or dividends.

Capex execution delays

Medium

Dahej expected Q3 (was H1); Sotanala formulation April (was H2). Minor slips, but if further delays occur, capex normalization and CDMO revenue ramp could slip. Interest capitalization and working capital cycles prolonged.

International business early-stage execution risk

Medium

International target ₹500 Cr over 5Y at 40–50% CAGR is ambitious. Currently ~5% of revenue. Registrations, CDMO deals, partner relationships are all nascent. Long cycle time (1–2Y per registration), regulatory complexity, and competition from China pose risks.

Management

Score 7/10. Clear, transparent, and granular. Rajesh Aggarwal provides detailed answers on product pipeline, capex, strategy. Acknowledges headwinds (monsoon, El Niño, supply chain) without deflection. Some answers hedged (e.g., international timelines, margin expansion pace), but no evident NDA shields or non-answers. Mixed. Kaeros scaling on track; ₹114 Cr H1 run-rate validates 50%+ CAGR path. But core business volume negative, margins compressing, capex timelines slipped slightly. Working capital management unaddressed despite deterioration. Track record shows execution but not flawless pace.

What to watch next
  • 1 · Q3 FY27 (Dec 2026)

    Dahej DCS plant full commissioning; capex normalization begins

  • 2 · Q4 FY27 (Mar 2027)

    Sotanala formulation unit startup; CDMO formulation launches

  • 3 · FY28 (Apr–Jun 2027)

    Kaeros network fully established; 60 products live; southern markets rollout

Execution risk on capex (Dahej, Sotanala) and margin pressure from weather/commodity volatility remain near-term headwinds.

Informational and educational content only. Not investment advice.